Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Fragoso RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, Monjazeb AM.

Int J Radiat Oncol Biol Phys. 2018 Apr 22. pii: S0360-3016(18)30695-3. doi: 10.1016/j.ijrobp.2018.04.038. [Epub ahead of print]

PMID:
29891204
2.

Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs.

Withers SS, Moore PF, Chang H, Choi JW, McSorley SJ, Kent MS, Monjazeb AM, Canter RJ, Murphy WJ, Sparger EE, Rebhun RB.

Dev Comp Immunol. 2018 May 31;87:64-74. doi: 10.1016/j.dci.2018.05.022. [Epub ahead of print]

PMID:
29859828
3.

Obesity as an immune-modifying factor in cancer immunotherapy.

Canter RJ, Le CT, Beerthuijzen JMT, Murphy WJ.

J Leukoc Biol. 2018 May 15. doi: 10.1002/JLB.5RI1017-401RR. [Epub ahead of print] Review.

PMID:
29762866
4.

Skeletal Muscle Metrics on Clinical 18F-FDG PET/CT Predict Health Outcomes in Patients with Sarcoma.

Foster B, Boutin RD, Lenchik L, Gedeon D, Liu Y, Nittur V, Badawi RD, Li CS, Canter RJ, Chaudhari AJ.

J Nat Sci. 2018;4(5). pii: e502.

5.

Palliative Care Training and Decision-Making for Patients with Advanced Cancer: A Comparison of Surgeons and Medical Physicians.

Bateni SB, Canter RJ, Meyers FJ, Galante JM, Bold RJ.

Surgery. 2018 Apr 27. pii: S0039-6060(18)30078-3. doi: 10.1016/j.surg.2018.01.021. [Epub ahead of print]

PMID:
29709369
6.

Serum C-reactive Protein and Neutrophil/Lymphocyte Ratio After Neoadjuvant Radiotherapy in Soft Tissue Sarcoma.

Yanagisawa M, Gingrich AA, Judge S, Li CS, Wang N, Thorpe SW, Kirane AR, Bold RJ, Monjazeb AM, Canter RJ.

Anticancer Res. 2018 Mar;38(3):1491-1497.

PMID:
29491077
7.

Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma.

Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, D'Ambrosio L, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, Gronchi A; A Collaborative Effort from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG).

Eur J Surg Oncol. 2018 Jun;44(6):810-815. doi: 10.1016/j.ejso.2018.01.086. Epub 2018 Feb 5.

PMID:
29452860
8.

Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas.

Henderson T, Chen M, Darrow MA, Li CS, Chiu CL, Monjazeb AM, Murphy WJ, Canter RJ.

J Surg Res. 2018 Mar;223:207-214. doi: 10.1016/j.jss.2017.11.016. Epub 2017 Dec 22.

PMID:
29433875
9.

Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.

Canter RJ, Grossenbacher SK, Foltz JA, Sturgill IR, Park JS, Luna JI, Kent MS, Culp WTN, Chen M, Modiano JF, Monjazeb AM, Lee DA, Murphy WJ.

J Immunother Cancer. 2017 Dec 19;5(1):98. doi: 10.1186/s40425-017-0305-7.

10.

Comparison of common risk stratification indices to predict outcomes among stage IV cancer patients with bowel obstruction undergoing surgery.

Bateni SB, Bold RJ, Meyers FJ, Canter DJ, Canter RJ.

J Surg Oncol. 2018 Mar;117(3):479-487. doi: 10.1002/jso.24866. Epub 2017 Oct 16.

PMID:
29044598
11.

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients.

David EA, Andersen SW, Beckett LA, Melnikow J, Kelly K, Cooke DT, Brown LM, Canter RJ.

Ann Thorac Surg. 2017 Nov;104(5):1665-1672. doi: 10.1016/j.athoracsur.2017.05.071. Epub 2017 Sep 28.

12.

Reply.

David EA, Canter RJ.

Ann Thorac Surg. 2017 Oct;104(4):1437-1438. doi: 10.1016/j.athoracsur.2017.03.052. No abstract available.

PMID:
28935316
13.

The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer.

David EA, Clark JM, Cooke DT, Melnikow J, Kelly K, Canter RJ.

J Thorac Oncol. 2017 Nov;12(11):1636-1645. doi: 10.1016/j.jtho.2017.08.008. Epub 2017 Aug 24. Review.

14.

Response to "Reframing the Concept of 'No Treatment' in Advanced NSCLC".

David EA, Canter RJ.

J Thorac Oncol. 2017 Aug;12(8):e126-e127. doi: 10.1016/j.jtho.2017.05.007. No abstract available.

PMID:
28748823
15.

Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis.

Gingrich AA, Bateni SB, Monjazeb AM, Darrow MA, Thorpe SW, Kirane AR, Bold RJ, Canter RJ.

Ann Surg Oncol. 2017 Oct;24(11):3252-3263. doi: 10.1245/s10434-017-6019-8. Epub 2017 Jul 24.

PMID:
28741123
16.

The modified frailty index to predict morbidity and mortality for retroperitoneal sarcoma resections.

Park JS, Bateni SB, Bold RJ, Kirane AR, Canter DJ, Canter RJ.

J Surg Res. 2017 Sep;217:191-197. doi: 10.1016/j.jss.2017.05.025. Epub 2017 May 11.

PMID:
28587892
17.

Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis.

David EA, Daly ME, Li CS, Chiu CL, Cooke DT, Brown LM, Melnikow J, Kelly K, Canter RJ.

J Thorac Oncol. 2017 Mar;12(3):437-445. doi: 10.1016/j.jtho.2016.11.2221. Epub 2017 Jan 18.

18.

Canine cancer immunotherapy studies: linking mouse and human.

Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JI, Culp WTN, Sparger EE, Rebhun RB, Monjazeb AM, Murphy WJ, Canter RJ.

J Immunother Cancer. 2016 Dec 20;4:97. doi: 10.1186/s40425-016-0200-7. eCollection 2016. Review.

19.

Lung resection is safe and feasible among stage IV cancer patients: An American College of Surgeons National Surgical Quality Improvement Program analysis.

Bateni SB, David EA, Bold RJ, Cooke DT, Meyers FJ, Canter RJ.

Surgery. 2017 May;161(5):1307-1314. doi: 10.1016/j.surg.2016.11.002. Epub 2016 Dec 20.

PMID:
28011006
20.

Predictors of residual disease after unplanned excision of soft tissue sarcomas.

Gingrich AA, Elias A, Michael Lee CY, Nakache YN, Li CS, Shah DR, Boutin RD, Canter RJ.

J Surg Res. 2017 Feb;208:26-32. doi: 10.1016/j.jss.2016.08.096. Epub 2016 Sep 8.

21.

Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.

Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ.

Expert Opin Biol Ther. 2017 Mar;17(3):313-324. doi: 10.1080/14712598.2017.1271874. Epub 2016 Dec 23. Review.

22.

Increased Rates of Prolonged Length of Stay, Readmissions, and Discharge to Care Facilities among Postoperative Patients with Disseminated Malignancy: Implications for Clinical Practice.

Bateni SB, Meyers FJ, Bold RJ, Canter RJ.

PLoS One. 2016 Oct 25;11(10):e0165315. doi: 10.1371/journal.pone.0165315. eCollection 2016.

23.

Conservative management of desmoid tumors is safe and effective.

Park JS, Nakache YP, Katz J, Boutin RD, Steffner RJ, Monjazeb AM, Canter RJ.

J Surg Res. 2016 Sep;205(1):115-20. doi: 10.1016/j.jss.2016.06.028. Epub 2016 Jun 16.

PMID:
27621007
24.

Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?

Canter RJ.

Surg Oncol Clin N Am. 2016 Oct;25(4):861-72. doi: 10.1016/j.soc.2016.05.013. Epub 2016 Aug 5. Review.

PMID:
27591503
25.

Does Lymph Node Count Influence Survival in Surgically Resected Non-Small Cell Lung Cancer?

David EA, Cooke DT, Chen Y, Nijar K, Canter RJ, Cress RD.

Ann Thorac Surg. 2017 Jan;103(1):226-235. doi: 10.1016/j.athoracsur.2016.05.018. Epub 2016 Jul 26.

PMID:
27469339
26.

Delayed phlegmon with gallstone fragments masquerading as soft tissue sarcoma.

Goodman LF, Bateni CP, Bishop JW, Canter RJ.

J Surg Case Rep. 2016 Jun 22;2016(6). pii: rjw106. doi: 10.1093/jscr/rjw106.

27.

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival.

David EA, Canter RJ, Chen Y, Cooke DT, Cress RD.

Ann Thorac Surg. 2016 Oct;102(4):1101-9. doi: 10.1016/j.athoracsur.2016.04.058. Epub 2016 Jun 9.

28.

Natural killer cell immunotherapy to target stem-like tumor cells.

Grossenbacher SK, Canter RJ, Murphy WJ.

J Immunother Cancer. 2016 Apr 19;4:19. doi: 10.1186/s40425-016-0124-2. eCollection 2016.

29.

Older Age Modifies Oncologic Outcome Following Radiotherapy in Soft-tissue Sarcoma: A Subtype-specific SEER Analysis.

Yuen NK, Li CS, Monjazeb AM, Borys D, Bold RJ, Canter RJ.

Anticancer Res. 2016 Apr;36(4):1745-50.

PMID:
27069154
30.

Immune targeting of cancer stem cells in gastrointestinal oncology.

Canter RJ, Grossenbacher SK, Ames E, Murphy WJ.

J Gastrointest Oncol. 2016 Apr;7(Suppl 1):S1-S10. doi: 10.3978/j.issn.2078-6891.2015.066. Review.

31.

Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

Monjazeb AM, Kent MS, Grossenbacher SK, Mall C, Zamora AE, Mirsoian A, Chen M, Kol A, Shiao SL, Reddy A, Perks JR, T N Culp W, Sparger EE, Canter RJ, Sckisel GD, Murphy WJ.

Clin Cancer Res. 2016 Sep 1;22(17):4328-40. doi: 10.1158/1078-0432.CCR-15-3026. Epub 2016 Mar 15.

32.

Locally Advanced Spiroadenocarcinoma in the Regional Axilla of a Breast Cancer Patient: Hallmarks of Definitive Diagnosis and Management.

Gingrich AA, Fung MA, Konia T, Canter RJ.

Rare Tumors. 2015 Sep 7;7(3):5912. doi: 10.4081/rt.2015.5912. eCollection 2015 Sep 7.

33.

Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells.

Ames E, Canter RJ, Grossenbacher SK, Mac S, Smith RC, Monjazeb AM, Chen M, Murphy WJ.

Oncoimmunology. 2015 Jun 5;4(9):e1036212. eCollection 2015 Sep.

34.

NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.

Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez-Cunningham J, Sckisel GD, Urayama S, Monjazeb AM, Fragoso RC, Sayers TJ, Murphy WJ.

J Immunol. 2015 Oct 15;195(8):4010-9. doi: 10.4049/jimmunol.1500447. Epub 2015 Sep 11.

35.

Surgery in high-volume hospitals not commission on cancer accreditation leads to increased cancer-specific survival for early-stage lung cancer.

David EA, Cooke DT, Chen Y, Perry A, Canter RJ, Cress R.

Am J Surg. 2015 Oct;210(4):643-7. doi: 10.1016/j.amjsurg.2015.05.002. Epub 2015 Jun 27.

36.

Older age impacts radiotherapy-related outcomes in soft tissue sarcoma.

Yuen NK, Li CS, Monjazeb AM, Borys D, Bold RJ, Canter RJ.

J Surg Res. 2015 Dec;199(2):494-504. doi: 10.1016/j.jss.2015.06.020. Epub 2015 Jun 16.

37.

Sarcopenia: Current Concepts and Imaging Implications.

Boutin RD, Yao L, Canter RJ, Lenchik L.

AJR Am J Roentgenol. 2015 Sep;205(3):W255-66. doi: 10.2214/AJR.15.14635. Epub 2015 Jun 23. Review.

PMID:
26102307
38.

Surgical approach for soft tissue sarcoma: standard of care and future approaches.

Canter RJ.

Curr Opin Oncol. 2015 Jul;27(4):343-8. doi: 10.1097/CCO.0000000000000202. Review.

PMID:
26049275
39.

Current perioperative outcomes for patients with disseminated cancer.

Bateni SB, Meyers FJ, Bold RJ, Canter RJ.

J Surg Res. 2015 Jul;197(1):118-25. doi: 10.1016/j.jss.2015.03.063. Epub 2015 Mar 27.

40.

Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.

Brown EG, Canter RJ, Bold RJ.

J Surg Oncol. 2015 Mar;111(3):293-8. doi: 10.1002/jso.23812. Epub 2014 Oct 20.

PMID:
25330934
41.

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.

Canter RJ, Ames E, Mac S, Grossenbacher SK, Chen M, Li CS, Borys D, Smith RC, Tellez J, Sayers TJ, Monjazeb AM, Murphy WJ.

BMC Cancer. 2014 Oct 10;14:756. doi: 10.1186/1471-2407-14-756.

42.

Hospital readmissions: necessary evil or preventable target for quality improvement.

Brown EG, Burgess D, Li CS, Canter RJ, Bold RJ.

Ann Surg. 2014 Oct;260(4):583-9; discussion 589-91. doi: 10.1097/SLA.0000000000000923.

43.

Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis.

Naing KW, Monjazeb AM, Li CS, Lee LY, Yang A, Borys D, Canter RJ.

J Surg Oncol. 2015 Feb;111(2):158-64. doi: 10.1002/jso.23780. Epub 2014 Sep 1.

44.

Relative value units poorly correlate with measures of surgical effort and complexity.

Shah DR, Bold RJ, Yang AD, Khatri VP, Martinez SR, Canter RJ.

J Surg Res. 2014 Aug;190(2):465-70. doi: 10.1016/j.jss.2014.05.052. Epub 2014 May 23.

45.

Outcomes of pancreaticoduodenectomy: where should we focus our efforts on improving outcomes?

Brown EG, Yang A, Canter RJ, Bold RJ.

JAMA Surg. 2014 Jul;149(7):694-9. doi: 10.1001/jamasurg.2014.151.

PMID:
24849180
46.

Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.

Canter RJ, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, Monjazeb AM.

Ann Surg Oncol. 2014 May;21(5):1616-23. doi: 10.1245/s10434-014-3543-7. Epub 2014 Feb 20.

47.

Text messaging among residents and faculty in a university general surgery residency program: prevalence, purpose, and patient care.

Shah DR, Galante JM, Bold RJ, Canter RJ, Martinez SR.

J Surg Educ. 2013 Nov-Dec;70(6):826-34. doi: 10.1016/j.jsurg.2012.05.003. Epub 2012 Jun 15.

48.

Comparative morbidity and mortality from cervical or thoracic esophageal anastomoses.

Shah DR, Martinez SR, Canter RJ, Yang AD, Bold RJ, Khatri VP.

J Surg Oncol. 2013 Dec;108(7):472-6. doi: 10.1002/jso.23423. Epub 2013 Sep 21.

PMID:
24108568
49.

Extremity soft tissue tumor surgery by surgical specialty: a comparison of case volume among oncology and non-oncology-designated surgeons.

Canter RJ, Smith CA, Martinez SR, Goodnight JE Jr, Bold RJ, Wisner DH.

J Surg Oncol. 2013 Sep;108(3):142-7. doi: 10.1002/jso.23372. Epub 2013 Jul 3.

PMID:
23893351
50.

Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities.

Wasif N, Smith CA, Tamurian RM, Christensen SD, Monjazeb AM, Martinez SR, Canter RJ.

JAMA Surg. 2013 Jul;148(7):632-9. doi: 10.1001/jamasurg.2013.113.

PMID:
23552630

Supplemental Content

Loading ...
Support Center